Agenus Cell-Therapy Unit MiNK Therapeutics Makes IPO Filing Public >AGEN
Agenus Cell-Therapy Unit MiNK Therapeutics Makes IPO Filing Public >AGEN...…
Börse:
1,499$
3,36%
Echtzeit-Aktienkurs Agenus Inc.
Bid:
1,448$
Ask:
1,549$
Nachrichten zur Agenus Inc. Aktie
Agenus subsidiary inks collaboration agreement with Ginkgo Bioworks
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
New Agenus Subsidiary, SaponiQx, Builds Innovative Adjuvant Platform and Forms Collaboration with Ginkgo Bioworks
LEXINGTON, Mass. and BOSTON, Sept. 10, 2021 /PRNewswire/ -- Agenus Inc. ("Agenus"), an immuno-oncology company with an extensive pipeline of…
New Agenus Subsidiary, SaponiQx, Builds Innovative Adjuvant Platform and Forms Collaboration with Ginkgo Bioworks
Development of saponin molecules designed to provide high-efficacy and long-lasting protection for pandemic vaccines Development of saponin molecules designed to…
Investors Cheer As Agenus Chugs Along
Shares of Agenus Inc. (AGEN), which have nearly doubled in value year-to-date, trade around $6....…
Agenus Multiple Value-Adding Events Ahead
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Why Agenus Fell by Over 4% on Monday
Investors were spooked by some ugly numbers in the companys latest earnings report....…
Agenus inc (AGEN) Q2 2021 Earnings Call Transcript
AGEN earnings call for the period ending June 30, 2021....…
Agenus (AGEN) Reports Q2 Loss, Misses Revenue Estimates
Agenus (AGEN) delivered earnings and revenue surprises of -54.17% and -36.75%, respectively, for the quarter ended June 2021. Do the…
Recap: Agenus Q2 Earnings
Shares of Agenus (NASDAQ:AGEN) moved higher by 2.1% in pre-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share…
AGENUS INC: 8-K Report
FORM 8-K...…
Agenus Corporate Update and Second Quarter 2021 Financial Report
LEXINGTON, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive…
Agenus Q2 Earnings Preview
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
AGENUS INC: 8-K Report
8-K...…
Agenus to Provide Corporate Update and Second Quarter 2021 Financial Report
Conference Call on Monday, August 9, 2021, at 8:30 a.m. ET Conference Call on Monday, August 9, 2021, at 8:30…
Agenus to Participate in Resistance-Focused Oncology Panel at the William Blair Biotech Focus Conference 2021
LEXINGTON, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline…
Agenus receives $200M payment as part of agreement with Bristol-Myers Squibb
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Agenus says its Bristol Myers Squibb licensing deal has up to $1.3 billion in milestone payments
Shares of Agenus Inc. were up 2.0% in premarket trading on Tuesday after the company said a licensing deal…
Agenus Closes $200M Upfront BMS Collaboration and Announces FDA Acceptance of IND for Partnered Anti-TIGIT Bispecific Antibody, AGEN1777
LEXINGTON, Mass., July 06, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive…
Agenus: What Now
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Why Agenus Stock Is Marching Higher Today
The biotech took a major step toward becoming a commercial-stage cancer company....…
Agenus Gains As Balstilimab US Application Accepted For Review In Cervical Cancer
read more...…
Agenus Announces U.S. FDA Acceptance and Priority Review of Balstilimab Biologics License Application for the Treatment of Recurrent or Metastatic Cervical Cancer
LEXINGTON, Mass., June 17, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive…
AGENUS INC: 8-K Report
8-K...…
Why Agenus Stock Is Jumping Today
There was some positive news, but it probably wasnt a huge catalyst for the stock....…
Agenus to Participate in Fireside Chat at the Jefferies 2021 Virtual Healthcare Conference
LEXINGTON, Mass., June 01, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline…
Agenus/Bristol-Myers Squibb Deal Makes For A Strong Buy
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Bristol-Myers (BMY) Teams Up With Agenus for Antibody Program
Bristol-Myers (BMY) obtains exclusive license for Agenus antibody program, AGEN1777, for an upfront payment of $200 million and up to…
2 Grossly Undervalued Biotech Stocks That Could Double Your Money
Aurinia Pharmaceuticals and Agenus might be poised for a healthy growth spurt....…
Thinking about buying stock in Agenus, Lucira Health, Ford, SINTX Technologies, or Qualtrics International?
NEW YORK, May 19, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AGEN, LHDX, F, SINT, and XM. To…
Agenus (AGEN) Soars on Global License Deal With Bristol-Myers
Agenus (AGEN) inks a definitive agreement with Bristol-Myers, wherein it will grant license to its bispecific antibody program AGEN1777 and…
BMS signs cancer therapy deal worth $1.5bn with Agenus
As part of the agreement, BMS will pay $200m upfront to Agenus, which is also eligible for up to $1.36bn…
XFRA : AJ81: Aussetzung/Suspension
DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:
THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME …
XFRA : AJ81: Wiederaufnahme/Resumption
FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.
THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING…
Why Agenus Stock Skyrocketed Today
The biotech announced a big licensing deal with Bristol Myers Squibb....…
Agenus rises 22% on up to $1.5B deal with Bristol-Myers Squibb
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Mid-Day Market Update: TOMI Environmental Solutions Falls After Q1 Results; Agenus Shares Jump
Midway through trading Tuesday, the Dow traded down 0.16% to 34,272.59 while the NASDAQ rose 0.69% to 13,470.97. The S&P…
Agenus, Stealth BioTherapeutics leads healthcare gainers; Evofem Biosciences, Seelos Therapeutics among major losers
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Thinking about buying stock in Evofem Biosciences, Agenus, Naked Brand, China Hgs Real Estate, or Palantir Technologies?
NEW YORK, May 18, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EVFM, AGEN, NAKD, HGSH, and PLTR. To…
Agenus Grants Bristol Myers Squibb License To Bispecific Antibody Program, AGEN1777
NEW YORK CITY (dpa-AFX) - Clinical-stage immuno-oncology company Agenus Inc. (NASDAQ: AGEN) announced an agreement under which Bristol-Myers Squibb Co.…
XFRA : INSTRUMENT_SUSPENSION EQUBF_01
Instrument ID [6557] (AJ81 - US00847G7051) suspended...…
AGENUS INC: 8-K Report
8-K...…
Bristol Myers Squibb and Agenus ink exclusive global license for antibody program
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Agenus Inc (AGEN) Q1 2021 Earnings Call Transcript
AGEN earnings call for the period ending April 30, 2021....…
AGENUS INC: 8-K Report
FORM 8-K...…
Agenus EPS beats by $0.04, misses on revenue
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Agenus Corporate Update and First Quarter 2021 Financial Report
LEXINGTON, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive…
Agenus to Present at the 2021 ASCO Annual Meeting
LEXINGTON, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline…
Agenus to Provide Corporate Update and First Quarter 2021 Financial Report
Conference Call on Thursday, May 6, 2021 at 8:30 a.m. ET Conference Call on Thursday, May 6, 2021 at 8:30…
Agenus Submits Balstilimab Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer
LEXINGTON, Mass., April 19, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive…